3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
116
Carcinoma, Non-Small-Cell Lung
101
Carcinoma, Renal Cell
67
Colorectal Neoplasms
46
Neoplasm Metastasis
40
Squamous Cell Carcinoma of Head and Neck
38
Carcinoma, Hepatocellular
38
Neoplasms
35
Lung Neoplasms
34
Stomach Neoplasms
33
Urinary Bladder Neoplasms
22
Hodgkin Disease
20
Carcinoma, Transitional Cell
20
Brain Neoplasms
20
Pancreatic Neoplasms
18
Ovarian Neoplasms
18
Prostatic Neoplasms
16
Head and Neck Neoplasms
16
Colonic Neoplasms
16
Skin Neoplasms
15
Sarcoma
14
Glioblastoma
14
Adenocarcinoma Of Esophagus
14
Triple Negative Breast Neoplasms
13
Carcinoma, Merkel Cell
13
Small Cell Lung Carcinoma
12
Rectal Neoplasms
12
Esophageal Neoplasms
12
Breast Neoplasms
12
Uveal Melanoma
11
Interventions
tazemetostat
1
relatlimab
1
durvalumab
1
brigimadlin
1
bintrafusp alfa protein, human
1
Nivolumab
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Tertiary Lymphoid Structures
×
Nivolumab
×
1 year
×
Clear all
NCT04095208
2026-04-21
CONGRATS
Institut Bergonié
Phase 2
Completed
68 enrolled